Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.

[1]  Charles Y. Lin,et al.  Discovery of a selective inhibitor of Doublecortin Like Kinase 1 , 2020, Nature Chemical Biology.

[2]  Jun Peng,et al.  Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments , 2020, Cancers.

[3]  A. Lin,et al.  Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.

[4]  R. Vogel,et al.  CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells , 2019, Pharmaceuticals.

[5]  Samantha Dale Strasser,et al.  Tissue-Specific Oncogenic Activity of KRASA146T. , 2019, Cancer discovery.

[6]  K. Ueno,et al.  Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer , 2018, AntiCancer Research.

[7]  Y. Hata,et al.  Doublecortin-like kinase 1 compromises DNA repair and induces chromosomal instability , 2018, Biochemistry and biophysics reports.

[8]  S. Tavangar,et al.  DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  Min Liu,et al.  DCLK1 promotes epithelial‐mesenchymal transition via the PI3K/Akt/NF‐κB pathway in colorectal cancer , 2018, International journal of cancer.

[10]  Michael Peyton,et al.  Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer , 2018, Cell.

[11]  Samantha Dale Strasser,et al.  Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis , 2018, Science Signaling.

[12]  E. Feldman,et al.  Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization , 2018, bioRxiv.

[13]  J. Murray,et al.  Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). , 2017, Journal of medicinal chemistry.

[14]  S. Knapp,et al.  Characterization of a highly selective inhibitor of the Aurora kinases. , 2017, Bioorganic & medicinal chemistry letters.

[15]  T. Wang,et al.  Functional implication of Dclk1 and Dclk1-expressing cells in cancer , 2017, Small GTPases.

[16]  Gerald C. Chu,et al.  Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism , 2017, Nature Communications.

[17]  S. Gygi,et al.  Proteome-Wide Protein Expression Profiling Across Five Pancreatic Cell Lines , 2017, Pancreas.

[18]  J. Yates,et al.  DCLK1 phosphorylates the microtubule‐associated protein MAP7D1 to promote axon elongation in cortical neurons , 2017, Developmental neurobiology.

[19]  Takafumi Yoshida,et al.  Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1 , 2017, Molecular Cancer Research.

[20]  R. May,et al.  Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells , 2017, Molecular Cancer.

[21]  Weiwen Dai,et al.  Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. , 2016, Structure.

[22]  Jian Liu,et al.  DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[23]  H. Koga,et al.  Pancreatic DCLK1 marks quiescent but oncogenic progenitors: a possible link to neuroendocrine tumors. , 2016, Stem cell investigation.

[24]  R. May,et al.  Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. , 2016, Cancer research.

[25]  A. S. Nateri,et al.  Spheroid-Formation (Colonosphere) Assay for in Vitro Assessment and Expansion of Stem Cells in Colon Cancer , 2016, Stem Cell Reviews and Reports.

[26]  Miao Tang,et al.  miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1. , 2016, Biochemical and biophysical research communications.

[27]  S. Steinbacher,et al.  Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site , 2016, Acta crystallographica. Section D, Structural biology.

[28]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[29]  B. Honig,et al.  Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. , 2016, Cell stem cell.

[30]  P. Krawczyk,et al.  Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients , 2016, Clinical and Translational Oncology.

[31]  Zhenfeng Duan,et al.  The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer , 2016, Oncotarget.

[32]  R. May,et al.  Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells , 2016, Journal of carcinogenesis & mutagenesis.

[33]  C. Hoogenraad,et al.  Microtubule‐binding protein doublecortin‐like kinase 1 (DCLK1) guides kinesin‐3‐mediated cargo transport to dendrites , 2016, The EMBO journal.

[34]  S. Arii,et al.  Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis , 2016, PloS one.

[35]  Fumiaki Sato,et al.  miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1 , 2016, Molecular Cancer Research.

[36]  Jeremy D O'Connell,et al.  Proteome-wide quantitative multiplexed profiling of protein expression: carbon-source dependency in Saccharomyces cerevisiae , 2015, Molecular biology of the cell.

[37]  S. Lightfoot,et al.  Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism , 2015, Oncotarget.

[38]  T. Wang,et al.  Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal , 2015, Oncotarget.

[39]  P. Jänne,et al.  Development of small molecules targeting the pseudokinase Her3. , 2015, Bioorganic & medicinal chemistry letters.

[40]  S. Islam,et al.  Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells , 2015, Oncotarget.

[41]  Zujiang Yu,et al.  Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth , 2015, Scientific Reports.

[42]  A. Wittinghofer,et al.  Structural Characterization of LRRK2 Inhibitors. , 2015, Journal of medicinal chemistry.

[43]  W. Tierney,et al.  DCLK1 Is Detectable in Plasma of Patients with Barrett’s Esophagus and Esophageal Adenocarcinoma , 2015, Digestive Diseases and Sciences.

[44]  R. May,et al.  DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma , 2014, Oncotarget.

[45]  P. Jänne,et al.  Pharmacological Targeting of the Pseudokinase Her3 , 2014, Nature chemical biology.

[46]  S. Lightfoot,et al.  Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition , 2014, Oncotarget.

[47]  T. Wang,et al.  XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. , 2014, Cancer letters.

[48]  P. Nordlund,et al.  The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.

[49]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[50]  Shibing Deng,et al.  Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.

[51]  R. May,et al.  Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1 , 2014, Molecular Cancer.

[52]  Lorne Zinman,et al.  Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis , 2014, Nature Neuroscience.

[53]  Linheng Li,et al.  Brief Report: Dclk1 Deletion in Tuft Cells Results in Impaired Epithelial Repair After Radiation Injury , 2014, Stem cells.

[54]  Linheng Li,et al.  Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[55]  R. Lothe,et al.  The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer , 2014, Epigenetics.

[56]  R. Postier,et al.  DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer , 2013, PloS one.

[57]  J. Gleeson,et al.  Doublecortin-like kinase enhances dendritic remodelling and negatively regulates synapse maturation , 2013, Nature Communications.

[58]  R. Kageyama,et al.  Dclk1 distinguishes between tumor and normal stem cells in the intestine , 2012, Nature Genetics.

[59]  Collin M. Stultz,et al.  Molecular Basis for Specific Regulation of Neuronal Kinesin-3 Motors by Doublecortin Family Proteins , 2012, Molecular cell.

[60]  Bob van de Water,et al.  Combining Doublecortin-Like Kinase Silencing and Vinca Alkaloids Results in a Synergistic Apoptotic Effect in Neuroblastoma Cells , 2012, Journal of Pharmacology and Experimental Therapeutics.

[61]  C. Bellows,et al.  DCLK1 immunoreactivity in colorectal neoplasia , 2012, Clinical and experimental gastroenterology.

[62]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[63]  E. Halperin,et al.  Matrin 3 Binds and Stabilizes mRNA , 2011, PloS one.

[64]  N. Gray,et al.  Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.

[65]  U. McDermott,et al.  Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 , 2011, ACS medicinal chemistry letters.

[66]  R. Versteeg,et al.  Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. , 2010, Endocrine-related cancer.

[67]  N. Osheroff,et al.  DNA topoisomerase II, genotoxicity, and cancer. , 2007, Mutation research.

[68]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[69]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[70]  G. Eichele,et al.  The evolving doublecortin (DCX) superfamily , 2006, BMC Genomics.

[71]  James C. Wang,et al.  Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  A. Mayeda,et al.  CDK11 Complexes Promote Pre-mRNA Splicing* , 2003, The Journal of Biological Chemistry.

[73]  C. Walsh,et al.  DCAMKL1 Encodes a Protein Kinase with Homology to Doublecortin that Regulates Microtubule Polymerization , 2000, The Journal of Neuroscience.

[74]  Wei Li,et al.  DNA topoisomerase IIβ and neural development , 2000 .

[75]  M. Mizuguchi,et al.  High expression of doublecortin and KIAA0369 protein in fetal brain suggests their specific role in neuronal migration. , 1999, The American journal of pathology.

[76]  K. Sossey-Alaoui,et al.  DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar to doublecortin (DCX). , 1999, Genomics.

[77]  C. Austin,et al.  Eukaryotic DNA topoisomerase IIβ , 1998 .

[78]  F M Richards,et al.  Areas, volumes, packing and protein structure. , 1977, Annual review of biophysics and bioengineering.

[79]  G. Heiduschka,et al.  Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies , 2016, European Archives of Oto-Rhino-Laryngology.

[80]  A. Maitra,et al.  DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. , 2014, Gastroenterology.

[81]  C Sander,et al.  Polarity as a criterion in protein design. , 1989, Protein engineering.